about
Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsAffibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.Vismodegib: the proof of concept in Basal cell carcinoma.Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rashMechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell deathAdverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerIntracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsA Novel Technique to Detect EGFR Mutations in Lung Cancer.Molecular markers that predict response to colon cancer therapy.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.Current status of cetuximab for the treatment of patients with solid tumors.Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.Cutaneous vasculitis in breast cancer treated with chemotherapy.EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®)).HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer.Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Cetuximab in refractory skin cancer treatment.Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes.Cell death-based treatment of lung adenocarcinoma.
P2860
Q28534094-218D6045-2D6B-4FF8-A0E2-4CFC7B2860FBQ33279445-BDC2242A-6FCB-411A-978F-BC45C72BF685Q33358967-B83E5B3F-B27B-4C4C-948C-D132C32FCDEBQ33734736-47523987-9BF1-47DE-B0DA-FBA593954741Q33798783-52330BBA-5D40-40B5-9E07-2E0F3C8F75ECQ33939339-8694CFFA-7F29-4E23-B1F5-807187CCC4D6Q33983656-CBE117FA-5377-4C22-A451-89F127B02CC9Q34751465-06D7BEBB-AE47-4EE6-9813-5E61E55EF225Q35059625-FAA5081A-4EC0-40DD-ADC0-2BECB047D064Q35152542-48BA6470-23F1-4D04-857D-4ABB5AD2D8B2Q35623056-F13A6D0B-6F1E-4827-BB52-09510B1AF3AFQ36028935-BF3090B5-4E00-45CF-8A20-03832A43CE33Q36150356-31A2F56C-2AD5-4450-A144-655CB45F8DC1Q36217126-A8CFEE77-9938-4172-9609-B1249ED960BEQ36364973-081CC2EC-BC42-41A8-A56A-B479F603D89AQ36425973-B02B0274-7429-4735-94D2-AFAE88FF3B2FQ36481002-74B12FDE-DB86-4856-8EEB-595D3C8B3737Q36634272-8E59CABF-F687-4A7D-8763-CD835EA12040Q36963933-8972237B-D9D6-4F00-B1B7-D257A2051C0BQ37174372-A417B1EC-7EC7-47E8-B7CC-1A2B629495F7Q37327248-848F1B98-A337-4AEF-ABF9-CD9B0B7E459FQ39263953-AFA796D5-813A-42FF-84ED-128B3FEFB46AQ39379613-3349EE7E-29E4-4E07-901D-35BCB9AC274BQ40190986-613A8659-E886-4C5F-8350-756E7E222DFAQ40310402-5F1B5A6B-1483-4823-B010-FB8B2EE38F0BQ40971778-25487AFC-BA54-41C3-A76F-81E0F0EE0C9AQ41833201-3E35B5E2-9284-451D-8915-B6B0B85D540CQ42180892-1BD9D8A6-578C-44F5-86E1-B2CAFAF3499DQ47711273-0C377CE8-3700-49B8-9F35-E1F34387B39E
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacological background of EGFR targeting.
@ast
Pharmacological background of EGFR targeting.
@en
type
label
Pharmacological background of EGFR targeting.
@ast
Pharmacological background of EGFR targeting.
@en
prefLabel
Pharmacological background of EGFR targeting.
@ast
Pharmacological background of EGFR targeting.
@en
P2093
P356
P1433
P1476
Pharmacological background of EGFR targeting.
@en
P2093
J L Fischel
L Castillo
M C Etienne-Grimaldi
P Formento
P304
P356
10.1093/ANNONC/MDH257
P577
2004-07-01T00:00:00Z